Search - tctmd.com

Displaying 101 - 120 of 962

Sort: Relevancy | Date

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Physician and Management Partnerships: Benefits and Challenges

Presenter: Robert J. Applegate, Charles E. Chambers, Megan Berlinger

October 29, 2016

News Industry News

Academic Research Organization HCRI Changes Name to The Baim Institute for Clinical Research

October 27, 2016

News Industry News

Corindus Vascular Robotics Receives FDA Clearance for Next Generation Robotic System

October 27, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

Todd Neale

October 18, 2016

News Daily News

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Caitlin E. Cox

October 04, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Industry News

SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

October 03, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Todd Neale

September 29, 2016

News Industry News

Edwards INSPIRIS RESILIA Valve Receives CE Mark

September 29, 2016

News Daily News

Were Problems With the Point-of-Care Device Used in ROCKET AF Kept From the FDA? BMJ Says Yes

Todd Neale

September 28, 2016

News Daily News

A Step in the Wrong Direction: Weight-Loss Efforts Could Be Hampered by Addition of Wearable Device

Yael L. Maxwell

September 21, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Industry News

Shockwave Medical Announces FDA Clearance of the Company’s Lithoplasty® System, the First and Only Technology to Use Sound Waves to Treat Calcified Peripheral Artery Disease

September 16, 2016

News Daily News

TAVR 伴随中风风险：PARTNER 研究深入审查和 CoreValve 数据揭示了机遇和未知

Shelley Wood

September 13, 2016

Advertisement

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Physician and Management Partnerships: Benefits and Challenges

Academic Research Organization HCRI Changes Name to The Baim Institute for Clinical Research

Corindus Vascular Robotics Receives FDA Clearance for Next Generation Robotic System

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

TCTMD’s Top 10 Most Popular Stories for September 2016

TCTMD’s Top 10 Most Popular Stories for September 2016

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Edwards INSPIRIS RESILIA Valve Receives CE Mark

Were Problems With the Point-of-Care Device Used in ROCKET AF Kept From the FDA? BMJ Says Yes

A Step in the Wrong Direction: Weight-Loss Efforts Could Be Hampered by Addition of Wearable Device

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Shockwave Medical Announces FDA Clearance of the Company’s Lithoplasty® System, the First and Only Technology to Use Sound Waves to Treat Calcified Peripheral Artery Disease

TAVR 伴随中风风险：PARTNER 研究深入审查和 CoreValve 数据揭示了机遇和未知

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content